Promotion of beauty products to young girls may fuel compulsive habits and potential health risks, says watchdog Italian regulators are investigating Sephora and Benefit Cosmetics over the apparent use of “covert marketing strategies” to sell beauty products to young girls that might be fuelling an unhealthy skincare obsession called “ cosmeticorexia ”. The Italian Competition Authority said it wa...
Promotion of beauty products to young girls may fuel compulsive habits and potential health risks, says watchdog Italian regulators are investigating Sephora and Benefit Cosmetics over the apparent use of “covert marketing strategies” to sell beauty products to young girls that might be fuelling an unhealthy skincare obsession called “ cosmeticorexia ”. The Italian Competition Authority said it was looking into promotions for skincare products such as face masks, serums and anti-ageing creams that in some cases appeared to target girls under 10. Continue reading...
Waldemarus/iStock via Getty Images Pharming Group ( PHAR ) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, issued a positive opinion recommending marketing authorization for Joenja, a treatment for a rare form of immunodeficiency. With its marketing authorization application, the Dutch drugmaker seeks EU approval of Joenja for patients aged 12 year...
Waldemarus/iStock via Getty Images Pharming Group ( PHAR ) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, issued a positive opinion recommending marketing authorization for Joenja, a treatment for a rare form of immunodeficiency. With its marketing authorization application, the Dutch drugmaker seeks EU approval of Joenja for patients aged 12 years and older with activated phosphoinositide 3-kinase delta syndrome (APDS), which is estimated to affect roughly 1–2 individuals per million globally. The oral inhibitor of phosphoinositide 3-kinase delta is already available in countries, including the U.S. and U.K. The European Commission will next review the decision from EMA’s human medicines committee within about two months. If authorized, Joenja will be indicated across 27 EU member states as well as Norway, Iceland, and Liechtenstein as the first approved therapy for APDS. More on Pharming Pharming Group N.V. 2025 Q4 - Results - Earnings Call Presentation Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript Pharming Group N.V. (PHAR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow Pharming outlines $405M–$425M 2026 revenue target as Joenja and RUCONEST drive growth Pharming beats top-line estimates; introduces FY26 outlook
The dollar index (DXY00 ) today rose to a 1-week high and is up by +0.05%. The dollar is slightly higher today as the risk of a protracted Iran war boosts safe-haven demand for the dollar. Also, today’s +3% rally in crude oil prices is pushing inflation expectations higher, potentially...
The dollar index (DXY00 ) today rose to a 1-week high and is up by +0.05%. The dollar is slightly higher today as the risk of a protracted Iran war boosts safe-haven demand for the dollar. Also, today’s +3% rally in crude oil prices is pushing inflation expectations higher, potentially...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.94%. June E-mini S&P futures (ESM26 ) are down -0.90%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.94%. June E-mini S&P futures (ESM26 ) are down -0.90%, and June E-mini Nasdaq futures...
Hardikkumar Joshi Philadelphia Federal Reserve Bank President Anna Paulson sees the long-run federal funds rate closer to the SEP median of 3.1%. The Federal Reserve, in its March Summary of Economic Projections, made no changes to its median interest rate projections. In the longer run, the policy rate continues to be seen at 3.0%. Paulson was speaking before the Macroeconomics and Monetary Polic...
Hardikkumar Joshi Philadelphia Federal Reserve Bank President Anna Paulson sees the long-run federal funds rate closer to the SEP median of 3.1%. The Federal Reserve, in its March Summary of Economic Projections, made no changes to its median interest rate projections. In the longer run, the policy rate continues to be seen at 3.0%. Paulson was speaking before the Macroeconomics and Monetary Policy Conference hosted by the Federal Reserve Bank of San Francisco. She gave her views on what the rapid advance of AI can mean for the U.S. economy and what it means for monetary policy. "When I talk to businesses, I hear genuine enthusiasm. But I also hear about cautious implementation. The big productivity effects, if they come, seem likely to mostly lie ahead of us," said Paulson. Paulson presents three productivity scenarios that can impact the long-run federal funds rate: Under the low-productivity scenario, the rate would be relatively low. For example, before the pandemic, the median FOMC participant had a projection for the longer-run federal funds rate of just 2.5%. Under the medium-productivity scenario, the rate would be higher. Something like 3.1%. Under the high-productivity scenario, the rate would be higher still. One plausible value would be the upper end of the SEP's central tendency for the long-run federal funds rate, which was 3.5% in March. "When productivity growth is higher, there are more investment opportunities and a stronger demand for capital, and this puts upward pressure on interest rates," noted the Philadelphia Fed president. In January, the Philadelphia Fed president had said she still feels "cautiously optimistic on inflation" after the latest data, reiterating her view for additional interest-rate cuts later this year. "We're in a different position today," said Paulson. "Inflation has been above our 2% target for six years. While we've made significant progress, inflation is still 2.8%, not 2%. Long-term inflation expectations are consiste...
Following a sharp dip before $4,100 per ounce on March 23, gold rebounded dramatically, surging past $4,500 per ounce this morning after President Donald Trump extended an ongoing pause in U.S. attacks on Iran's energy facilities by 10 days to April 6. This nearly 10% rally in gold in a matter of days sent gold stocks higher too, with shares of SSR Mining (NASDAQ: SSRM) surging 17.5% in the week t...
Following a sharp dip before $4,100 per ounce on March 23, gold rebounded dramatically, surging past $4,500 per ounce this morning after President Donald Trump extended an ongoing pause in U.S. attacks on Iran's energy facilities by 10 days to April 6. This nearly 10% rally in gold in a matter of days sent gold stocks higher too, with shares of SSR Mining (NASDAQ: SSRM) surging 17.5% in the week through 11 a.m. ET Friday. However, there's a reason why SSR Mining is among this week's top-performing gold stocks . Beyond the gold rush, SSR Mining made a couple of major announcements this week, including a share repurchase program, because management believes the stock is worth a lot more than where it is trading today. Image source: Getty Images. Continue reading
The euro zone suffered the biggest inflation jump this month since Russia invaded Ukraine in 2022, according to economists assessing the fallout from war in the Middle East.
The euro zone suffered the biggest inflation jump this month since Russia invaded Ukraine in 2022, according to economists assessing the fallout from war in the Middle East.